Freshly Funded ImCheck Goes After Gamma Delta T-Cells

$53m Series B Financing Will Advance ImCheck Therapeutics’ Pipeline

ImCheck’s $53m series B financing will be used to develop antibodies that activate gamma delta T-cells for use against cancer and autoimmune diseases, its CEO tells Scrip.

Immune_System
Gamma delta T-cells have active role in body's early immune response • Source: Shutterstock

Freshly funded via a $53m series B financing round, France-based ImCheck Therapeutics SAS can now enter the clinic with its lead monoclonal antibody and test its potential to activate gamma delta T-cells that kill malignant tumors, the biotech’s CEO and its chief medical officer told Scrip.

“Our first trial will start early in 2020 withICT01 and is based on comprehensive translational research supporting its potential to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer